Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Acute Coronary Syndrome (ACS)
4.7
$ 19.50
In stock
(787)
Product Description
Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?
Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy - ScienceDirect
Antiplatelet therapy after percutaneous coronary intervention - EuroIntervention
Conversations With Experts Dual Antiplatelet Therapy Post PCI: When and How to De-Escalate - American College of Cardiology
Tailoring P2Y12 Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet
Antiplatelet therapy in acute coronary syndrome - Brown - 2017 - Continuing Cardiology Education - Wiley Online Library
Pretreatment with P2Y12 Inhibitor in Patients with Acute Coronary Syndromes - American College of Cardiology
Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting - Research and Practice in Thrombosis and Haemostasis
/cdn.vox-cdn.com/uploads/chorus_asset/file/24941627/1690279363.jpg "Week 3: New York Giants at San Francisco 49ers - Live Updates, Picks - Mile High Report")
